Latest Conference Articles

Updated data from the PHOEBE trial show that pyrotinib plus capecitabine improved overall survival in patients with HER2-positive breast cancer compared with lapatinib plus capecitabine.

Data from a pooled analysis confirm that patients who self-identify as Black or Hispanic can safely benefit from treatment with palbociclib plus endocrine therapy for hormone receptor–positive, HER2-negative advanced breast cancer.

A non-chemotherapy–based targeted regimen comprised of tucatinib, palbociclib, and letrozole was found to prolong central nervous system (CNS) progression-free survival (PFS) in patients with hormone receptor–positive, HER2-positive breast cancer.

Compared with tamoxifen, aromatase inhibitors were revealed to be more effective in reducing the rate of recurrence in ER+ breast cancer among premenopausal women receiving ovarian suppression.

Alexandra S. Zimmer, MD, discusses treatment options for patients with HER2-positive breast cancer who have developed brain metastasis.

Data presented at the San Antonio Breast Cancer Sympsium found that in patients with a low HER2 immunohistochemistry (IHC) score of 0 or 1+, poor agreement in the evaluation of these patients exist using standard HER2 assays.

Patients with higher Oncotype DX scores are more likely to complete the recommended 5 years of endocrine therapy.

Early results from a phase 1 study show promise for datopotamab deruxtecan for patients with advanced or metastatic triple-negative breast cancer.

Results from prespecified subgroup analyses of the phase KEYNOTE-522 study were presented during 2021 SABCS.

Final results from the phase 3 PALLAS study show the addition of palbociclib to endocrine therapy lacks benefit for patients with early hormone receptor-positive, HER2-negative breast cancer.

Updated results from the phase 3 3KEYNOTE-355 trial indicate a new standard of care for patients with metastatic triple-negative breast cancer in patients with a PD-L1 combined positive score of 10 or higher.

Improved invasive disease-free survival or overall survival rates for patients, regardless of hormone receptor status, was not improved with metformin, according to results of a phase 3 trial.

Research shows that tamoxifen treatment may lead to problems down the road in patients with primary breast cancer.

During a press briefing ahead of the 2021 San Antonio Breast Cancer Symposium, results from the phase 3 EMERALD trial were presented.

Imaging mass cytometry at the single-cell level may be a promising response prediction tool for immunotherapy in early triple-negative breast cancer.

In an epidemiological study, a 24-month lymphedema rate of 39.4% was the highest incidence of lymphedema observed among Black women.

A pooled analysis of results from the randomized phase 2 SAFIR02_BREAST and SAFIR-PI3K trials show promise for the use of multigene sequencing to select targeted therapy for metastatic breast cancer.

Findings from the phase 3 PADA-1 trial reveal promising progression-free survival results when treatment with fulvestrant/palbociclib follows treatment with an aromatase inhibitor plus palbociclib in a metastatic breast cancer subgroup.

In an interview with Targeted Oncology, Richard M. Stone, MD, discussed challenging subtypes of acute myeloid leukemia and therapies available to treat them.

Rajneesh Nath provides an expert's take on the evolution of risk stratification, molecular testing, and treatment of acute myeloid leukemia.

The phase 2b AIPAC study, Eftilagimod alpha was found to improve overall survival in metastatic breast cancer along with a tolerable safety profile.

Data presented at an ASCO Plenary session found that digitally monitoring patient-reported outcomes helped to improve outcomes and quality of life.

Subasumstat was found to have a manageable safety profile along with preliminary anti-tumor activity in patients with advanced or metastatic solid tumors or relapsed/refractory lymphoma.

Joseph A. Sparano, MD, who recently gave a talk during the 19th Annual School of Breast Oncology, discusses prolonging responses to therapy in patients with advanced breast cancer.

In the Chinese population of the global INVICTUS trial, ripretinib was found to have a manageable safety profile and produced a good response rate.

Compared with systemic therapy administered after cytoreductive nephrectomy, active surveillance was an option for some patients with metastatic renal cell carcinoma.

Compared with sunitinib, the combination of nivolumab an ipilimumab produced better long-term responses, with overall survival approaching 5 years.

New findings suggest that understanding subtypes of non-clear cell renal cell carcinoma is important for personalizing treatment.

James Brugarolas, MD, PhD, discusses updated survival data in patients with metastatic renal cell carcinoma.

The frontline combination of lenvatinib and pembrolizumab is under investigation as a treatment option for patients with non-clear cell renal cell carcinoma in the recently launched phase 2 KEYNOTE-B61 trial.